Taysha Gene Therapies Inc. (TSHA)
NASDAQ: TSHAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
TSHA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.44B
- EPS (TTM)
- -$0.41
- Dividend yield
- None
- 52-week range
- 3.69 – 7.30
- Day range
- 4.27 – 4.46
- Volume / Avg
- 3.76M / 3.24M
- Beta
- —
- Shares outstanding
- 325.83M
- Next earnings
- Nov 3, 2026
52-week range
TSHA stock today
Taysha Gene Therapies (TSHA) closed at $4.43 on Oct 7, up 0.91% (+$0.04), versus the S&P 500's 0.22% decline. At this level, TSHA sits in the middle of its 52-week range of $3.69 to $7.30: 39.3% below the high, set on May 6, 2026 and 20.0% above the low. TSHA is down 19.5% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 6.1%.
Taysha Gene Therapies has posted a net loss over the last twelve months (EPS of -$0.41), so its P/E ratio is not meaningful. Taysha Gene Therapies's next earnings report is expected on Nov 3, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Taysha Gene Therapies
Company profile- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- IPO year
- 2020
Earnings
Earnings history- Next report
- Nov 3, 2026
- EPS estimate
- $-0.14
Taysha Gene Therapies peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MAZEMaze Therapeutics Inc. | 26.25 | -0.68% | $1.46B | vs TSHA |
| INBXInhibrx Biosciences Inc. | 93.36 | -0.05% | $1.37B | vs TSHA |
| IMCRImmunocore Holdings plc ADR | 29.41 | -0.47% | $1.51B | vs TSHA |
| COAGHemab Therapeutics Holdings Inc. | 28.70 | +1.16% | $1.34B | vs TSHA |
| REPLReplimune Group Inc. | 13.20 | -0.38% | $1.24B | vs TSHA |
| IMTXImmatics N.V. | 7.45 | -0.67% | $1.13B | vs TSHA |
| VORVor Biopharma Inc. | 18.78 | +2.57% | $1.11B | vs TSHA |
| MESOMesoblast Limited ADR | 13.94 | +2.42% | $1.81B | vs TSHA |
Indexes, lists and sector
Taysha Gene Therapies stock FAQ
What is Taysha Gene Therapies's stock price today?
TSHA last traded at $4.43 as of Oct 7, 4:00 PM EDT, up 0.91% on the day. Prices are delayed at least 15 minutes.
When is Taysha Gene Therapies's next earnings date?
Taysha Gene Therapies is expected to report earnings on Tuesday, November 3, 2026. Analysts expect EPS of $-0.14.
What is the TSHA 52-week high?
The 52-week high for TSHA is $7.30 and the 52-week low is $3.69. The stock is currently 39.3% below its high.